Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer

Endocrine therapy is the preferred option for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.1 However, first-line chemotherapy is used in approximately half of this patient population, notably in the context of organ failure or resistance to endocrine therapy.2,3 In these patients, chemotherapy is frequently stopped, despite disease stabilisation, because of acute and cumulative toxic effects.4 Switching to maintenance endocrine therapy after first-line induction chemotherapy has been proposed to improve disease control and to maintain quality of life (QOL).